A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP

• Status: Recruiting
• Trial end date: 2022-06-30
• Target enrollment: 0
• Participant gender: All

Summary

A phase 2 study to assess tolerability, safety, pharmacokinetics and effect of AZP2006 at different doses versus placebo on cerebrospinal fluid biomarkers in 36 patients with progressive supranuclear palsy. The patient study duration is 29 weeks including a washout period.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AlzProtect SAS
• Treatments: Acetaminophen; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Male and female patients with probable or possible PSP

• Patients must be stable with their medication for at least 30 days prior to the inclusion visit.

Exclusion Criteria:

• Any history of clinically significant head trauma or cerebrovascular disease or recent history of substance abuse or alcohol abuse and deemed to be clinically significant by the Investigator.

• History of deep brain stimulator (DBS) surgery other than sham surgery for DBS clinical study.